Skip to content
buyModerate

Baker Bros. Advisors LP bought $1.4M of TRDA

owner at Entrada Therapeutics, Inc.. 178,044 shares at an average of $7.60, traded Nov 10, 2025, filed Nov 12, 2025.

Conviction score
46
Value
$1.4M
178,044 shares
Holdings after
4,664,924
+49% from before
From 52-week low
+45%
low $5.02, close $7.26
From 52-week high
-66%
high $21.59, as of Nov 10, 2025

Score components

  • Role
    10% owner
    +12
  • Trade size
    $1.4M at market
    +25
  • Relative to holdings
    Holdings up 49%
    +6
  • Price context
    66% below the 52-week high
    +8
  • Cluster
    No other insider buying within 14 days
    0
  • Repeat buying
    First buy in 90 days
    0
  • Track record
    Too few past buys to judge (0 with prices)
    0
  • Outside holder
    A 10% owner who is not an officer or director
    -5

What happened after comparable buys

Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.

Price around the trade, and since

From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.

TRDAOct 9, 2026 · close 5.67
Since filing Nov 12, 2025: -29.2%SPY +15.2% · excess -44.4%

Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™

Rows in this filing

Every transaction in Form 4 0001193125-25-278038, as filed. Open on EDGAR

DateTransactionSharesPriceValueHoldings afterFiled
Nov 10, 2025POpen-market purchase
Common Stockindirect: See Footnotes
+2,296$7.21$17k366,457Nov 12, 2025
Nov 10, 2025POpen-market purchase
Common Stockindirect: See Footnotes
+25,364$7.21$183k4,527,022Nov 12, 2025
Nov 10, 2025POpen-market purchase
Common Stockindirect: See Footnotes
+267$7.22$1,929366,724Nov 12, 2025
Nov 10, 2025POpen-market purchase
Common Stockindirect: See Footnotes
+2,947$7.22$21k4,529,969Nov 12, 2025
Nov 11, 2025POpen-market purchase
Common Stockindirect: See Footnotes
+1,059$7.39$7,827367,783Nov 12, 2025
Nov 11, 2025POpen-market purchase
Common Stockindirect: See Footnotes
+11,701$7.39$86k4,541,670Nov 12, 2025
Nov 11, 2025POpen-market purchase
Common Stockindirect: See Footnotes
+2,795$7.54$21k370,578Nov 12, 2025
Nov 11, 2025POpen-market purchase
Common Stockindirect: See Footnotes
+30,879$7.54$233k4,572,549Nov 12, 2025
Nov 12, 2025POpen-market purchase
Common Stockindirect: See Footnotes
+7,321$7.73$57k377,899Nov 12, 2025
Nov 12, 2025POpen-market purchase
Common Stockindirect: See Footnotes
+80,881$7.73$625k4,653,430Nov 12, 2025
Nov 12, 2025POpen-market purchase
Common Stockindirect: See Footnotes
+1,040$7.95$8,273378,939Nov 12, 2025
Nov 12, 2025POpen-market purchase
Common Stockindirect: See Footnotes
+11,494$7.95$91k4,664,924Nov 12, 2025

Related signals

Other insiders at Entrada Therapeutics, Inc. and this insider’s other filings.

ScoreCompanyInsiderValueHoldingsFiled
45Moderate
TRDAsell 2
Entrada Therapeutics, Inc.
MPM BioVentures 2014, L.P.
owner
$1.9M
259,837 shares
-6%
45Moderate
TRDAsell 2
Entrada Therapeutics, Inc.
Mpm Bioventures 2018, L.p.
owner
$1.9M
259,837 shares
-6%
40Moderate
TRDAsell 2
Entrada Therapeutics, Inc.
MPM BioVentures 2014, L.P.
owner
$617k
86,482 shares
-2%
40Moderate
TRDAsell 2
Entrada Therapeutics, Inc.
Mpm Bioventures 2018, L.p.
owner
$617k
86,482 shares
-2%
20Weak
TRDAsell 210b5-1
Entrada Therapeutics, Inc.
Nathan J Dowden
President & COO
$196k
15,010 shares
-7%
27Weak
TRDAsell 210b5-1
Entrada Therapeutics, Inc.
Kory James Wentworth
Chief Financial Officer
$214k
16,477 shares
-12%
20Weak
TRDAsell 210b5-1
Entrada Therapeutics, Inc.
Kory James Wentworth
Chief Financial Officer
$98k
7,988 shares
-5%
36Weak
TRDAbuy
Entrada Therapeutics, Inc.
Baker Bros. Advisors LP
owner
$262k
28,867 shares
+8%
26Weak
TRDAsell 310b5-1
Entrada Therapeutics, Inc.
Kory James Wentworth
Chief Financial Officer
$89k
8,910 shares
-7%
52Moderate
TRDAsell 3
Entrada Therapeutics, Inc.
5AM Ventures V, L.P.
owner
$1.8M
200,000 shares
-6%

Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.

Baker Bros. Advisors LP bought $1.4M of TRDA | InsiderTell